ALX Oncology Holdings Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALXO Nasdaq 2836 www.alxoncology.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ALX Oncology Holdings Inc.

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - Jan 22nd, 2025 9:01 pm
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors - Jan 22nd, 2025 1:00 pm
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI - Jan 21st, 2025 10:00 pm
3 US Penny Stocks With Market Caps Under $100M To Watch - Jan 8th, 2025 8:05 pm
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? - Jan 7th, 2025 2:40 pm
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Jan 7th, 2025 1:00 pm
Top Midday Decliners - Dec 19th, 2024 6:48 pm
Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold' - Dec 19th, 2024 1:57 pm
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium - Dec 18th, 2024 1:00 pm
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 - Dec 12th, 2024 1:00 pm
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer - Dec 10th, 2024 2:00 pm
3 US Penny Stocks With Market Caps Over $30M To Consider - Nov 26th, 2024 8:09 pm
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference - Nov 26th, 2024 1:00 pm
ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Nov 21st, 2024 2:35 pm
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer - Nov 14th, 2024 1:00 pm
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Nov 7th, 2024 9:00 pm
ALX Oncology Announces November Investor Conference Participation - Nov 4th, 2024 1:00 pm
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 - Nov 1st, 2024 9:30 pm
Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc - Oct 10th, 2024 11:04 pm
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference - Sep 9th, 2024 12:00 pm